FDA approves Theratechnologies' lipodystrophy drug Egrifta

11/10/2010 | Wall Street Journal, The

Theratechnologies has gained FDA approval of Egrifta as an injectable treatment for lipodystrophy, a condition characterized by high fat accumulation, in HIV patients. The once-daily drug, generically known as tesamorelin, will be marketed by Theratechnologies' partner Merck Serono.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC